{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:50:38Z","timestamp":1789098638756,"version":"build-2803163510"},"reference-count":94,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CSIC","award":["BILAT23016"],"award-info":[{"award-number":["BILAT23016"]}]},{"name":"AEI, Spain","award":["PID2024-159248OB-I00"],"award-info":[{"award-number":["PID2024-159248OB-I00"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERNED"],"award-info":[{"award-number":["CIBERNED"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n HNA"},{"DOI":"10.13039\/100014440","name":"MCIU","doi-asserted-by":"crossref","award":["FPU21\/01392"],"award-info":[{"award-number":["FPU21\/01392"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/13543784.2026.2667249","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:12:09Z","timestamp":1777363929000},"page":"351-367","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Innovative therapies under clinical development for ALS treatment: small molecules"],"prefix":"10.1080","volume":"35","author":[{"given":"Loreto","family":"Martinez-Gonzalez","sequence":"first","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Sanchez-Santos","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chen Sarah","family":"Huang","sequence":"additional","affiliation":[{"name":"Taipei Medical University and National Health Research Institutes","place":["New Taipei City, Taiwan"]},{"name":"Taipei Medical University","place":["New Taipei City, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gil","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12435-9"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37505"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.38801"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030300"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001447.pub3"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33746"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17582024.2024.2402216"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-07994-2"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00171-6"},{"key":"e_1_3_6_12_1","unstructured":"Businesswire [Internet]. (CA): Amylyx Pharmaceuticals; [cited 2026 Mar 9]. Available from: https:\/\/www.businesswire.com\/news\/home\/20240308462671\/en\/Amylyx-Pharmaceuticals-Announces-Topline-Results-From-Global-Phase-3-PHOENIX-Trial-of-AMX0035-in-ALS"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.382985"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2178416"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.00363"},{"key":"e_1_3_6_16_1","unstructured":"Massachusetts General Hospital [Internet]. Massachusetts: Sean M. Healey & AMG Center for ALS; [cited 2026 Mar 9]. Available from: https:\/\/www.massgeneral.org\/neurology\/als\/news\/healeyamg-announces-platform-trial-update-fosigotifator"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00326-0"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01073-2"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40734-8"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.01.005"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae109"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101707"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082142"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.03.002"},{"key":"e_1_3_6_25_1","unstructured":"InFlectis BioScience [Internet]. Nantes: InFlectis BioScience; [cited 2026 Mar 9]. Available from: https:\/\/inflectisbioscience.reportablenews.com\/pr\/inflectis-positive-prelim-results-of-ifb-088-in-ph2-study"},{"key":"e_1_3_6_26_1","unstructured":"MND Association [Internet]. Northampton: MND Association; [cited 2026 Mar 9]. Available from: https:\/\/www.mndassociation.org\/research\/clinical-trials\/treatment-trials\/metformin"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00428-5"},{"key":"e_1_3_6_28_1","unstructured":"BiotechDispatch [Internet]. Deakin: PharmAust; [cited 2026 Mar 9]. Available from: https:\/\/biotechdispatch.com.au\/news\/pharmaust-says-reports-positive-interim-study-results-from-study-in-als"},{"key":"e_1_3_6_29_1","unstructured":"PRNewswire [Internet]. Chicago: Neurizon; [cited 2026 Mar 9]. Available from: https:\/\/www.prnewswire.com\/news-releases\/fda-clears-nuz-001-for-entry-into-healey-als-platform-trial-302639645.html"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206526"},{"key":"e_1_3_6_31_1","unstructured":"NeurologyLive [Internet]. Cranbury: NeurologyLive; [cited 2026 Mar 9]. Available from: https:\/\/www.neurologylive.com\/view\/fda-clears-pivotal-phase-3-prevails-study-pridopidine-early-rapidly-progressive-als"},{"key":"e_1_3_6_32_1","unstructured":"PRNewswire [Internet]. Chicago: ProJenX; [cited 2026 Mar 9]. Available from: https:\/\/www.prnewswire.com\/news-releases\/projenx-announces-removal-of-partial-clinical-hold-for-prosetin-program-by-fda-302101883.html"},{"key":"e_1_3_6_33_1","unstructured":"PRNewswire [Internet]. Chicago: ProJenX; [cited 2026 Mar 9]. Available from: https:\/\/www.prnewswire.com\/news-releases\/projenx-and-unlearn-announce-partnership-to-augment-als-clinical-trial-pro-101-with-digital-twin-model-302259147.html"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02862-z"},{"key":"e_1_3_6_35_1","unstructured":"PRG S&Tech [Internet]. Busan: PRG S&Tech Inc; [cited 2026 Mar 9]. Available from: http:\/\/eng.prgst.com\/bbs\/board.php?bo_table=news_media_en&wr_id=118&ckattempt=2"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106430"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61265-y"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110804"},{"key":"e_1_3_6_39_1","unstructured":"Molefy Pharma [Internet]. San Cristobal de la Laguna: Molefy Pharma; [cited 2026 Mar 9]. Available from: https:\/\/molefypharma.com\/en\/molefy-pharma-orphan-drug-designation-als\/"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205577"},{"key":"e_1_3_6_41_1","unstructured":"Verge Genomics [Internet]. San Francisco: Verge Genomics; [cited 2026 Mar 9]. Available from: https:\/\/www.vergegenomics.com\/news-blog\/verge-genomics-and-ferrer-announce-agreement-to-co-develop-clinical-stage-als-therapy-vrg50635"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132049"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28451"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28448"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf063"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01262-3"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2007.01.072"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100679"},{"key":"e_1_3_6_49_1","unstructured":"Prnewswire [Internet]. Chicago: Shanghai Zhimeng Biopharma Inc.; [cited 2026 Mar 9]. Available from: https:\/\/www.prnewswire.com\/news-releases\/zhimeng-biopharmas-investigational-drug-cb03-154-for-amyotrophic-lateral-sclerosis-has-achieved-the-first-patient-first-dose-milestone-in-the-phase-23-pivotal-clinical-trial-302599908.html"},{"key":"e_1_3_6_50_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07093268?term=NCT07093268&rank=1"},{"key":"e_1_3_6_51_1","unstructured":"Mitochon Pharmaceuticals [Internet]. Blue Bell: Mitochon Pharmaceuticals; [cited 2026 Mar 9]. Available from: https:\/\/www.mitochonpharma.com\/pipeline\/amyotrophic-lateral-sclerosis\/"},{"key":"e_1_3_6_52_1","unstructured":"Pharmaceutical Technology [Internet]. Mitochon Pharmaceuticals. [cited 2026 Mar 9]. Available from: https:\/\/www.pharmaceutical-technology.com\/news\/ema-approves-mitochon-neurogenerative-disease-study\/"},{"key":"e_1_3_6_53_1","unstructured":"NRG Therapeutics [Internet]. Stevenage: NRG Therapeutics Ltd; [cited 2026 Mar 9]. Available from: https:\/\/www.nrgtherapeutics.com\/news\/22\/51\/NRG-Therapeutics-Announces-First-Participants-Dosed-in-its-First-in-Human-Phase-1-Clinical-Trial-of-NRG5051-Which-is-Being-Developed-as-a-Disease-modifying-Treatment-for-ALSMND-and-Parkinsons.html"},{"key":"e_1_3_6_54_1","unstructured":"ClinicalTrials Arena [Internet]. London: QurAlis; [cited 2026 Mar 9]. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/quralis-qrl101-trial-topline-results\/"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104202"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1203"},{"key":"e_1_3_6_57_1","unstructured":"MND Association [Internet]. Northampton: MND Association; [cited 2026 Mar 9]. Available from: https:\/\/www.mndassociation.org\/research\/clinical-trials\/treatment-trials\/utreloxastat-ptc857"},{"key":"e_1_3_6_58_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05189106"},{"key":"e_1_3_6_59_1","unstructured":"Laboratory of Systems Pharmacology [Internet]. Harvard: Mark Alber\u2019s lab at MGH; [cited 2026 Mar 9]. Available from: https:\/\/labsyspharm.org\/lsp-news\/from-the-bench-the-lab-of-dr-mark-albers-at-mass-general-hospital\/"},{"key":"e_1_3_6_60_1","unstructured":"Raya Therapeutic [Internet]. Montreal: Raya Therapeutic Inc; [cited 2026 Mar 9]. Available from: https:\/\/www.rayatherapeutic.com\/post\/raya-therapeutic-announces-supportive-clinical-results-of-fasudil-rt1968-in-als-patients?lang=en"},{"key":"e_1_3_6_61_1","unstructured":"NeurologyLive [Internet]. Cranbury: NeurologyLive; [cited 2026 Mar 9]. Available from: https:\/\/www.neurologylive.com\/view\/patient-recruitment-complete-high-dose-cohort-oral-fasudil-phase-2-als"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2021-0042"},{"key":"e_1_3_6_63_1","unstructured":"GlobeNewswire [Internet]. El Segundo: AB Science; [cited 2026 Mar 9]. Available from: https:\/\/www.globenewswire.com\/news-release\/2025\/07\/24\/3120751\/0\/en\/AB-Science-has-received-approval-from-several-European-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-ALS.html"},{"key":"e_1_3_6_64_1","unstructured":"NeurologyLive [Internet]. Cranbury: NeurologyLive; [cited 2026 Mar 9]. Available from: https:\/\/www.neurologylive.com\/view\/late-breaking-phase-2b-paradigm-data-support-continued-development-primec-als"},{"key":"e_1_3_6_65_1","unstructured":"Prnewswire [Internet]. Chicago: NeuroSense Therapeutics Ltd.; [cited 2026 Mar 9]. Available from: https:\/\/www.prnewswire.com\/news-releases\/neurosense-receives-fda-clearance-to-initiate-pivotal-phase-3-trial-for-primec-in-als-302624616.html"},{"key":"e_1_3_6_66_1","unstructured":"ALS NewsToday [Internet]. (FL): NeuroSense Therapeutics Ltd.; [cited 2026 Mar 9]. Available from: https:\/\/alsnewstoday.com\/news\/aan-2025-primec-reduces-mirnas-linked-als-progression\/"},{"key":"e_1_3_6_67_1","unstructured":"PRNewswire [Internet]. Chicago: Transposon Therapeutics; [cited 2026 Mar 9]. Available from: https:\/\/www.prnewswire.com\/news-releases\/transposon-announces-tpn-101-selected-for-inclusion-in-the-phase-23-healey-als-platform-trial-building-on-the-success-of-phase-2-study-in-c9orf72-related-als-302466319.html"},{"key":"e_1_3_6_68_1","unstructured":"ALS NewsToday [Internet]. (FL): Athira Pharma; [cited 2026 Mar 9]. Available from: https:\/\/alsnewstoday.com\/news\/ath-1105-experimental-oral-therapy-found-safe-healthy-adults\/"},{"key":"e_1_3_6_69_1","unstructured":"GlobeNewswire [Internet]. El Segundo: Athira Pharma; [cited 2026 Mar 9]. Available from: https:\/\/www.globenewswire.com\/news-release\/2025\/05\/13\/3080344\/0\/en\/Athira-Pharma-to-Present-Data-from-First-in-Human-Phase-1-Clinical-Trial-of-ATH-1105-at-the-4th-Annual-ALS-Drug-Development-Summit.html"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53982-w"},{"key":"e_1_3_6_71_1","unstructured":"Pharmaceutical Technology [Internet]. Global data. [cited 2026 Mar 9]. Available from: https:\/\/www.pharmaceutical-technology.com\/data-insights\/fb-418-1st-bio-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval\/"},{"key":"e_1_3_6_72_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07321860"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.983853"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291285"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101169"},{"key":"e_1_3_6_76_1","unstructured":"Businesswire [Internet]. (CA): Tranquis Therapeutics; [cited 2026 Mar 9]. Available from: https:\/\/www.businesswire.com\/news\/home\/20211103005909\/en\/Tranquis-Therapeutics-Presents-Positive-Preclinical-Data-on-TQS-168-for-the-Treatment-of-ALS-at-Neuroscience-2021-Annual-Meeting"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773288"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1662197"},{"key":"e_1_3_6_79_1","unstructured":"clinicaltrial.be [Internet]. clinicaltrial.be. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrial.be\/en\/details\/458899?only_active=0&only_eligible=0&only_recruiting=0&per_page=20"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2025.2515900"},{"key":"e_1_3_6_81_1","unstructured":"Zydus [Internet]. Ahmedabad: Zydus; [cited 2026 Mar 9]. Available from: https:\/\/zyduslife.com\/investor\/admin\/uploads\/21\/83\/Zydus-announces-USFDA-Orphan-Drug-Designation-to-Usnoflast-for-the-treatment-of-Amyotrophic-Lateral-Sclerosis-(ALS).pdf"},{"key":"e_1_3_6_82_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05377424"},{"key":"e_1_3_6_83_1","unstructured":"MND Association [Internet]. Northampton: MND Association; [cited 2026 Mar 9]. Available from: https:\/\/www.mndassociation.org\/research\/clinical-trials\/treatment-trials\/darifenacin"},{"key":"e_1_3_6_84_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05860244"},{"key":"e_1_3_6_85_1","unstructured":"euclinicaltrials [Internet]. euclinicaltrials; [cited 2026 Mar 9]. Available from: https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2022-501624-14-00?lang=en"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01143-1"},{"key":"e_1_3_6_87_1","unstructured":"Spinogenix [Internet]. Los Angeles: Spinogenix; [cited 2026 Mar 9]. Available from: https:\/\/spinogenix.com\/press-release\/spinogenix-presents-topline-phase-2a-clinical-trial-results-for-spg302-a-first-in-class-als-treatment\/"},{"key":"e_1_3_6_88_1","unstructured":"GlobeNewswire [Internet]. El Segundo: Cytokinetics; [cited 2026 Mar 9]. Available from: https:\/\/www.globenewswire.com\/news-release\/2023\/03\/31\/2638547\/35409\/en\/%20Cytokinetics-Announces-COURAGE-ALS-Met-Criteria-for-Futility-at-Second-Interim-Analysis.html"},{"key":"e_1_3_6_89_1","unstructured":"TRICALS [Internet]. TRICALS; [cited 2026 Mar 9]. Available from: https:\/\/www.tricals.org\/news\/lighthouse-ii-study-terminated-after-interim-analysis"},{"key":"e_1_3_6_90_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05923905"},{"key":"e_1_3_6_91_1","unstructured":"euclinicaltrials [Internet]. euclinicaltrials; [cited 2026 Mar 9]. Available from: https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2024-511405-27-00?lang=en"},{"key":"e_1_3_6_92_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06647628"},{"key":"e_1_3_6_93_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06726577"},{"key":"e_1_3_6_94_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2026 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06527222"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241249436"},{"key":"e_1_3_6_96_1","unstructured":"Mass General Brigham [Internet]. Brigham: Mass General Brigham; [cited 2026 Mar 9]. Available from: https:\/\/www.massgeneralbrigham.org\/en\/about\/newsroom\/articles\/whats-the-latest-on-als-research-and-clinical-trials"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2667249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:51:19Z","timestamp":1779951079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2667249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/13543784.2026.2667249"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2667249","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}